# Daily Plan

Handoff from `pre_market` → `market_open`. Rewritten fresh each pre-market. `market_close` archives the prior day's plan to `memory/archive/plan_<YYYY-MM-DD>.md`.

## Date

2026-08-26 (pre_market ~08:28 ET) — DRY_RUN: false

## Planned buys

| ticker | target_qty | limit_price | stop_price | thesis |
|--------|------------|-------------|------------|--------|
| _(none)_ | — | — | — | No candidate scored ≥6/10 — see Notes. |

## Planned sells

| ticker | reason | notes |
|--------|--------|-------|
| _(none)_ | — | Book FLAT (0/8) — no open positions to exit. |

## Trailing stop conversions (market_open actions)

| ticker | current_stop_id | current_stop_price | action | target_new_stop | basis |
|--------|-----------------|-------------------|--------|-----------------|-------|
| _(none)_ | — | — | — | — | — |

## Notes

**Outcome: NO BUYS today. Book stays FLAT (0/8, 100% cash, equity $97,328.01).** Fewer than 3 candidates scored ≥6/10 → per `pre_market.md` step 3 / MUST-NOT, plan fewer buys rather than lower the bar. `market_open` has nothing to execute today.

**Gates (all pass):**
- Clock: `is_open=false`, `next_open=2026-08-26T09:30 ET` → market opens today (Wed), not a holiday → proceed.
- Reconciliation 0/0 PASS: Alpaca `/v2/positions=[]` matches portfolio.md FLAT — zero divergence.
- Universe cache FRESH: screened 2026-08-23, `expires_on=2026-08-30`, 294 tickers.
- PEAD health FRESH + **NORMAL**: computed 2026-08-23, `expires_on=2026-08-30`, `realized_health_60d=+2.284%`, `n=91` → **standard 15% EPS bar, max 5 new/week** (no ELEVATED_BAR overlay).
- Regime **BULL** (SPY $765.79 > 200MA $704.98, per pead_health `spy_above_200ma=true`) → standard thresholds.
- **Macro-deferral NOT triggered:** pre-market S&P futures **UP ~+0.3%** (the "futures down >0.4%" leg fails); 10-yr ~4.7% elevated but both legs are required → standard bars.

**Candidates researched:**
- **FTNT (IT, in universe) — 5/10, DROPPED.** Clean strong beat (Q2 rep Jul 29: EPS $0.90 +20% surprise, rev $2.05B +25.6% YoY, raised FY guide $8.02–8.18B, 6-qtr streak). Reaction gap +8.6% but faded to +0.5% close (muted); vol 2.68x. **Drift is spent/reversed:** 52-wk high $172.09 on Aug-5 (20 sessions ago), now $153.66 = **−10.7% off high**; **5-day RS −2.46pp vs SPY** (underperforming) → PEAD step-f drop/heavily-downrank. **Piper Sandler downgrade→Neutral ($135→$90)** on a "multi-quarter show-me / renewal compares harden" thesis that matches the rollover. Sector XLK +2.86pp (positive) not enough to offset a reversed central drift 4 weeks post-report. Regulatory: shelf-reg CLEAN; BIS immaterial (cybersecurity software).
- **ROST (Consumer Discretionary, in universe) — 5/10, DROPPED.** Headline EPS $2.66 vs $1.94 (+37%) is inflated by a **one-time ~$0.60/sh IEEPA tariff refund ($253M)** → **clean surprise ~+6%, FAILS the 15% bar**; ~56% of the FY guide-raise ($8.61–8.77) is the same non-recurring item (UBS stayed Neutral flagging this). Comps +10% / 2nd straight 10% quarter and 6-qtr beat streak are operationally strong, but the earnings-**surprise** (the PEAD input) is non-recurring. Reaction Aug-21 gap +6.0% held to +4.4% close, vol 4.56x (very strong), Citi upgrade + multiple PT raises; 5-day RS +2.26pp — **but** −6% below the pre-earnings high and drift already **stalling** (Aug 24–25 flat on 0.83–0.98x volume). Signal-quality leg compromised → below 6.

**Screened out (no research needed / disqualified):** DE (Industrials, EPS surprise +8.7% < required >20% + streak≥2 → DQ); ADI (IT/semi, +3.3% surprise, stock −3.5% post-print → negative PEAD); PANW (reports Sep 1, no in-window catalyst); MRVL — **active watchlist name reports Thu Aug 27, inside the 3-day earnings window → cannot enter**; NVDA/CRM/CRWD (report this week, within 3-day window); MRK/PFE/VRTX (52-wk highs on the Merck/Moderna Phase-3 melanoma mRNA-vaccine catalyst Aug 19 — a clinical/sector catalyst, not an earnings-drift setup the a–i protocol scores; MRK extended at ATH → noted, not planned).

**Watchlist flags (this run):** HAE (Haemonetics) and CAVA added as `status: pending_review` — compelling non-universe Q2 catalysts (both ~+34% pops on beat + guide raise) but snippet-level only, full a–i deep-research pending, human-only to set `active`. See `watchlist.md` / `research_log.md`. No trade planned on either.

**Sanity vs strategy.md:** N/A for buys (none). Cash floor 100% ≥ 10% ✓; concurrent 0/8 ≤ 8 ✓; new-per-week 0/5 ≤ 5 ✓; no sector exposure. Regulatory flags among planned buys: none (no buys).
